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Abstract
Developing a vaccine against Chlamydia is key to combating widespread mortalities and
morbidities associated with this infection in koalas (Phascolarctos cinereus). In previous
studies, we have shown that two or three doses of a Recombinant Major Outer Membrane
Protein (rMOMP) antigen-based vaccine, combined with immune stimulating complex (ISC)
adjuvant, results in strong cellular and humoral immune responses in koalas. We have also
separately evaluated a single dose vaccine, utilising a tri-adjuvant formula that comprises
polyphosphazine based poly I: C and host defense peptides, with the same antigen. This
formulation also produced strong cellular and humoral immune responses in captive koalas.
In this current study, we directly compared the host immune responses of two sub-groups of
wild Chlamydia negative koalas in one population vaccinated with the rMOMP protein anti-
gen and adjuvanted with either the ISC or tri-adjuvant formula. Overall, both adjuvants pro-
duced strong Chlamydia-specific cellular (IFN-γ and IL-17A) responses in circulating
PBMCs as well as MOMP-specific and functional, in vitro neutralising antibodies. While the
immune responses were similar, there were adjuvant-specific immune differences between
the two adjuvants, particularly in relation to the specificity of the MOMP epitope antibody
responses.
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Introduction
Chlamydial infections are responsible for significant mortality and morbidity of mainland
koalas (Phascolarctos cinereus) and are one major factor threatening the long term future of
this iconic species [1–4]. The main species of Chlamydia that infects koalas is C. pecorum, and
virtually all koala populations are infected, with rates ranging from 10% to as high as 90% in
some regions [1]. Despite the significant advances in chlamydial research, a prophylactic vac-
cine to stabilize the population decline caused by chlamydial infections [5] has yet to be fully
developed.
Chlamydia is an intracellular bacterium with a unique biphasic developmental cycle, con-
sisting of two developmental forms, the non-dividing, but infectious, elementary bodies (EBs)
and the replicative, but non-infectious reticulate bodies (RBs) [6]. It is usually accepted that a
host requires the development of a balanced Th1 and Th2 protective immune response to ade-
quately control chlamydial infections [7]. Several small animal studies have confirmed the pro-
tective role of IFN-γ secreting CD4+T cells in chlamydial infection [8]. Recently, there is also
re-emerging evidence supporting the prominent role of B cells to elicit protective anti-Chla-
mydia antibodies [9]. The primary role of the neutralizing antibodies is to reduce the initial
infectious burden and further prevent secondary bacterial infections [10]. Once the bacterium
parasitises the host’s cells, the cell mediated immune response pathway contributes signifi-
cantly to protective immunity through IFN-γ secretion [11]. Whilst IL-17A is a strong recruiter
of neutrophils which secrete antimicrobial peptides and promote a Th1 immune response
against intracellular pathogens [12], other animal studies suggest that IL-17 plays a role in both
immune pathology and protection [13].
The chlamydial major outer membrane protein (MOMP) is the leading vaccine candidate
in chlamydial vaccine research, and our group has been developing a prototype vaccine utiliz-
ing recombinant chlamydial MOMP (rMOMP) as a vaccine antigen for koalas. Although the
choice of immunogenic antigen is of prime importance, selecting the right adjuvant to appro-
priately trigger the immune response is also essential. In this context, we have used two differ-
ent adjuvant formulations with differing properties, combined with rMOMP, to vaccinate
groups of koalas: ISC (immune stimulating complex) adjuvant [14–17] or Tri-adjuvant which
is a mixture of the three components (Polyphosphazine, poly I: C and host defense peptides)
[18].
In our previous koala vaccine trials, the ISC adjuvant was able to induce strong cellular and
humoral immune responses [14–17]. However, the ISC adjuvant requires two or three injec-
tions to promote a significant immune response. This is logistically problematic for wild koalas,
which would need to be tracked and re-captured, or kept in captivity for extended periods of
time, increasing the cost of the process as well as the stress experienced by the animal itself. A
trivalent adjuvant (Tri-Adj) containing polyphosphazine, poly I: C and host defense peptides,
has been developed to be effective with just a single dose [18]. In other species, this adjuvant
promoted a Th1 and Th2 balanced immune responses following a single injection [19–23]. In a
small preliminary trial in captive koalas (n = 6), we have shown that this adjuvant was safe to
use and elicited promising immune responses [18].
In the current study, we evaluated, in detail, both the cellular and humoral immune
responses of wild koalas vaccinated with rMOMP, combined either with (a) the single-dose
Tri-Adj or (b) three doses of ISC. Firstly, we evaluated the cellular response for each adjuvant
by measuring cytokine gene expression elicited by the peripheral blood mononuclear cells
(PBMCs) at defined post-vaccination time points. Secondly, we measured the neutralising anti-
bodies produced by vaccination and mapped the corresponding MOMP epitopes recognized
for both cohorts.
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Materials and Methods
Koalas
The koalas used in our study were sourced from a wild population of around 400 animals
located in South East Queensland. Prior to vaccination, all animals were examined and those
animals that (i) had no clinical evidence of chlamydiosis; and (ii) were negative at conjunctival
and genital sites following Chlamydia pecorum-species-specific qPCR screening [24] were
selected and all animals were breeding age (>1 year) of either sex, as assessed during the initial
capture event by qualified wildlife veterinarians. Two sub-sets of these animals have been vacci-
nated with an anti-C.pecorum vaccine and we analysed a further sub-set of these vaccinated
animals in the current study. The first group of 10 koalas (Cindy, Greg, Cherry, Maxwell, Kylie,
Paige, Janke, Squeek, Linky and Kelly) (Group A) were vaccinated with chlamydial rMOMP
protein (see below for details) mixed with the Tri-Adj. A second group of 5 koalas (Robyn,
Pepper, Maya, Hunky Harry and Winnic) (Group B) were vaccinated with rMOMP protein
mixed with ISC [17]. At the end of the trial, all koalas were successfully returned to their habitat
in accordance with regulatory approvals. None of the animals in our sub-study groups were
diseased or required treatment or euthanasia during the study period. Animals were captured
at a minimum of every 6 months and viewed from the ground weekly. All work was conducted
under permission from Queensland University of Technology’s Animal Ethics Committee
(AEC; Permit # 1200000122), the University of the Sunshine Coast AEC (ANA1380) and Sci-
entific Purposes Permit (WISP11532912).
Vaccines
Both vaccines consisted of C. pecorum rMOMP combined with either adjuvant (Tri-Adj or
ISC) and were implementing through subcutaneous route. We combined three rMOMP pro-
teins (A, F and G types) for the vaccine, as described previously [14, 17, 18]. Koala-specific C.
pecorumMOMP proteins were expressed and purified as per Kollipara et al. [14]. The purified
products were used for vaccination and ELISA assays. After vaccination, the animals were
released back into the wild and tracked with a wildlife telemetry system (K-Tracker, LX Solu-
tions Pty Ltd). The ISC vaccinated koalas were re-captured at 1 monthly interval to receive the
2nd and 3rd dose of the vaccine and a veterinary health examination.
Samples
Aluminium shafted cotton-tipped swabs (Copan, Interpath Services, Melbourne) were used to
collect samples from the conjunctiva of the left and right eye, as well as the urogenital sinus
(prostatic urethra in males), as previously described [18]. These swabs were used for measuring
the C. pecorum infection load using a C. pecorum-species-specific qPCR targeting the 16S
rRNA gene [24]. Blood samples were obtained from the cephalic vein into EDTA-containing
tubes and stored at 4°C for processing within 24 h of collection, to obtain PBMCs. After centri-
fugation at 1000 rpm for 5 mins, plasma was separated and used for ELISAs and C. pecorum in
vitro neutralisation assays. The samples were collected at 0 (pre-vaccinated), 2 and 6 months
post vaccination.
Cytokine assays
The blood samples were centrifuged within 4–8 h of collection to separate the plasma. The
PBMC were isolated by centrifugation on Ficoll-paque gradients (GE Healthcare, Rydalmere,
Australia) washed and suspended in 1ml RPMI 1640 T cell media supplemented with 5% foetal
calf serum, antibiotics and β-mercaptoethanol (0.001M) (Sigma) at a concentration of 2x106
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cells/ml. A 500 μl aliquot of cell suspension was used as the pre-stimulation sample. The
remaining cells were then stimulated with either mitogens (Ionomycin and PMA combination)
[25] or UV-inactivated C. pecorum EBs. After stimulation and incubation at 37°C with 5%
CO2, the cells were collected at 12 and 24 h post-stimulation time points. RNA extraction and
cDNA synthesis were completed for all these pre- and post-stimulation samples according to
our previously published protocol (21). The end products were utilized in qPCR assays to
determine the mRNA expression level as fold change for interferon gamma (IFN-γ), interleu-
kin 17A (IL-17A), interleukin 10 (IL-10), tumour necrosis factor alpha (TNF-α) and glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) [25–27]. GAPDH was used as reference to
normalise IFN-γ, IL-17A, IL-10 and TNF-α using the 2-ΔΔCT method (ΔΔCT = (Ct of target
gene—Ct of GAPDH) at 12 or 24 h time point–(Ct of target gene–Ct of GAPDH) at 0 time
point [28].
C. pecorum specific ELISA
Enzyme-linked immunosorbent assays were performed using purified rMOMP as per Kolli-
para et al. [14] and Khan et al.[18] on the plasma samples collected at 0, 2 and 6 month time
points post-vaccination.
C. pecorumMOMP peptide ELISA
We initially screened the plasma to identify the reacting epitopes for individual animals, using
the methods described previously [9]. Then we measured the individual peptide concentrations
as determined using our previously described ELISA methods [18]. Instead of using the whole
rMOMP protein, we used selected peptides for coating the ELISA plates at a concentration of
2μg/well in PBST. Post-incubation, the wells were washed 3x with PBST and the plasma sample
was serially diluted two fold at 1:200 dilution initially, and incubated at 4°C overnight. Plates
were then washed 3x in PBST and a sheep anti-koala IgG (1:8000 in PBST;[16]) was added. At
this point, plates were incubated for a further one hour at room temperature. After a further
three washes (PBS-T), HRP-conjugated rabbit anti-sheep IgG (1:1000, Southern Biotech /
Millipore, North Ryde, Australia) was added to wells and incubated at room temperature for 1
hr. Post incubation, plates were washed 4x with PBS and 50 μl ABTS [2, 20-azino-bis (3-ethyl-
benzothiazoline-6-sulphonic acid), Southern Biotech, Alabama, USA] solution was added and
incubated for 10 mins to observe the greenish color development. The reaction was stopped
with 1M sulphuric acid following color observation. The optical density was measured at 405
nm wavelength and the data was transformed into excel sheet for later analysis.
Koala-specific C. pecorum neutralising antibodies
We conducted in vitro neutralisation assays using the methodology of Kollipara et al. [14]
either on whole plasma or on plasma collected at 0, 2 and 6 month time points which had been
pre-adsorbed with one or more individual peptides [14]. All plasma samples were diluted at
1:10 prior to assay. The background neutralisation was determined by using koala plasma that
was Chlamydia negative. Percentage neutralization was then determined by subtracting this
background from each individual to determine the final neutralisation. The results were
expressed as fold change neutralisation.
C. pecorumMOMP peptide mapping
Biotinylated Pepscan ELISA was performed as previously described [9] to identify the specific
rMOMP epitopes produced by each vaccine in animals receiving either the ISC or Tri-Adj
Adjuvant Effect Immune Response in Koalas (Phascolarctos cinereus)
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adjuvants. Briefly, we designed 88 peptides with 15-mer peptides that spanned the full length
of koala C. pecorumMOMP F protein and used these individually in ELISA assays (or grouped)
as described above. The background for each plasma sample was calculated from the mean
plus twice the standard deviation of the negative wells (no plasma added). We scored samples
with an absorbance value greater than 0.5 as a positive response. In subsequent experiments,
we utilised only the positive peptides to coat the streptavidin plate at a concentration of 2μg/
well and performed the standard ELISA as described.
C. pecorumMOMP-peptide specific neutralising antibodies
We performed three types of neutralising assays by using the (a) whole plasma at 1/10 dilution
for either Tri-Adj or ISC cohort, (b) whole plasma at post-adsorption against either peptide 58
and 77 for tri-adjuvant or at post-adsorption against epitope 4 for ISC cohort and finally (c)
whole plasma at post-adsorption against either epitopes 4, 28, 41, 42, 58, 59 and 77 for Tri-Adj
cohort or 4, 28, 41, 42 for ISC cohort. We utilised the previously described novel protocol for
peptide adsorption [9].
Statistical analysis
Statistical analyses were performed using Graph-Pad Prism version 6 (Graph Pad Software, La
Jolla, CA, USA) and the P value for significance was set at 0.05. Data between cohorts was
analysed using one–way ANOVA Kruskal-Wallis (non-parametric) tests.
Results
There was a non-significant trend towards stronger IFN-γ and IL-17A
responses in animals immunised with the Tri-Adj compared to ISC
immunised animals
To evaluate differences in the immune response of koalas vaccinated with a C. pecorum
rMOMP-vaccine adjuvanted with either Tri-Adj or ISC, we vaccinated a cohort of koalas that
were clinically healthy at the time of vaccination and were Chlamydia PCR negative at both
urogenital and ocular sites (data not shown). Immune profiling of these vaccinated animals
revealed that 60% of the animals in both groups produced IFN-γ at 2 or 6 months post vaccina-
tion in response to stimulation of PBMCs with UV-inactivated EBs (elementary bodies) (6 out
of 10 for Tri-Adj and 3 out of 5 for ISC adjuvant). For those animals whose PBMCS expressed
IFN- γ in response to stimulation, the level of IFN-γ expression varied from 2.73 to 17.89-fold
for Tri-Adj and from 2.08 to 12.67-fold for ISC (Fig 1). We also observed differences among
the responders between the 2 month and 6 month time points. For the Tri-Adj responders the
highest expression was observed at 2 months, whereas, for ISC responders the highest IFN-γ
responses were at the 6-month time point. Overall, the IL-17A responses were lower than IFN-
γ, and only 40% of animals (4/10 Tri-Adj; 2/5 ISC) produced IL-17A responses to stimulation
above 1.0 fold. We did not observe any measurable expression for the anti-inflammatory cyto-
kine, IL-10 and TNF-α following stimulation of collected PBMCS from animals in either
cohort (Fig 2A–2D).
The kinetics of the total antibody (IgG) titres was similar in both cohorts,
though there was an increased trend towards higher plasma IgG titres in
ISC cohorts
Both vaccine formulations elicited strong anti-MOMP antibody levels following vaccination.
The Tri-Adj cohort produced titres of around 5x105 at 2 months post-vaccination, which
Adjuvant Effect Immune Response in Koalas (Phascolarctos cinereus)
PLOS ONE | DOI:10.1371/journal.pone.0156094 May 24, 2016 5 / 16
persisted up to 6 months. The ISC cohort produced a similar average titre at 2 months (7x105)
which increased (to 9x105) by the 6 months time point (p value 0.302) (Fig 3A). We also mea-
sured the antibody responses to individual peptides (selected ones) by ELISA (Fig 4A; 4B). The
titres for the individual epitopes varied from 0.3x103 to 2.8x103 EPT. Interestingly, there was
very little difference in titres for the individual epitopes, except for epitope 77 in a single koala
(Kelly) (Fig 4A).
Similar C. pecorum specific neutralising antibody potential was
produced by both adjuvants
To compare the function of antibody responses induced by either vaccine formulation, in vitro
neutralisation assays were performed with plasma from the Tri-Adj and ISC cohorts at 2 and 6
months post-vaccination. All samples were diluted 1:10 prior to testing their neutralising abil-
ity on C. pecorum infected cell culture mono-layers. Both adjuvant cohorts produced almost
identical in vitro neutralisation levels, with both groups having increased neutralisation levels
at 6 months compared to 2 months post vaccination (Fig 3B).
Epitope mapping identified two distinct anti- C. pecorumMOMP peptide
antibody profiles for the two adjuvant groups
We used the Pepscan approach [9] to examine the epitope specificity of the plasma antibody
response to vaccination in our Tri-Adj versus ISC adjuvant groups. In total, four C. pecorum
Fig 1. IFNγ (A, C) and IL17A (B, D) gene expression in koala PBMCs stimulated with UV inactivatedC. pecorum at 0, 2 and 6 months post vaccination.
The Tri-Adj (A, B) and ISC (C, D) cohort’s response are presented together (Fig 1 A-D). Results are expressed as fold increase compared to internal control
gene GAPDH.
doi:10.1371/journal.pone.0156094.g001
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MOMP peptides (4, 28, 41, and 42) were recognized in our C. pecorum peptide ELISA from
animals in each cohort with an additional three peptides recognised by koalas receiving the
Tri-Adj formulation only (58, 59 and 77). There was variability in the responses to these indi-
vidual peptides with peptide 4 recognised by 80% (4 out of 5) of the ISC cohort but only by
10% (1 out of 10) of the tri-adjuvant cohort. For the other epitopes, none were recognised by
100% of the animals in any cohort, although the most-broad recognition by the animals was
with epitopes 77 (8/10 of tri-adjuvant animals), 58/59 (5/10 tri-adjuvant animals), 41/42 (5/10
tri-adjuvant cohort) and 28 (4/5 ISC animals) (S1 Fig; Table 1).
The vaccine induced anti-epitope antibodies had neutralising ability,
either individually or in synergy with other epitopes
We examined the contribution of antibodies against individual epitopes or groups of epitopes,
to the observed in vitro neutralisation effect. We compared (a) whole plasma versus (b) plasma
pre-adsorbed against the most recognized peptides 58, 77 for Tri-Adj, and peptide 4 for ISC
versus (c) plasma pre-absorbed against epitopes 4, 28, 41, 42, 58, 59, 77 for Tri-Adj and 4, 28,
41, 42 for ISC. We evaluated the neutralising ability of each of these pre- and post-absorption
samples and compared the relative reduction of neutralisation ability in each case (Fig 5B and
5E). We found that most (if not all) of the individual anti-epitope antibodies contributed to in
Fig 2. IL10 (A, C) and TNFα (B, D) gene expression in koala PBMCs stimulated with UV inactivatedC. pecorum at 0, 2 and 6 months post vaccination. The
Tri-Adj (A, B) and ISC (C, D) cohorts are presented together (Fig 2 A-D). Results are expressed as fold increase compared to internal control gene GAPDH.
doi:10.1371/journal.pone.0156094.g002
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vitro neutralisation. In the case of the Tri-Adj vaccinated animals, anti-58 and anti-77 epitope
antibodies made a major contribution to the in vitro neutralisation effect (white bars in Fig
Fig 3. rMOMP specific IgG in plasma of vaccinated koalas was assayed by ELISA at 0, 2 and 6 months
post vaccination. IgG levels are expressed as end-point titers (EPT) and represent the mean ± SD of 10 and
5 koalas in the Tri-Adj and ISC cohort respectively (Fig 3A). Vaccine inducedC. pecorum percent
neutralisation in plasma is presented (Fig 3B) compared to pre-immunisation samples. All samples were
assayed at 1:10 dilution andC. pecorum EBs (50,000 IFU) were added to samples. The results are
expressed as the percentage neutralisation of post-immunized samples compared to that of the pre-
immunized and non-infected samples. Results are expressed as the mean ± SD of 10 and 5 koalas in the Tri-
adj and ISC cohort respectively. There was no significant difference between the two cohorts.
doi:10.1371/journal.pone.0156094.g003
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Fig 4. ELISA titers against individual peptide. Panel A (10 animals) for the Tri-adjuvanted vaccinated
animals and panel B (5 animals) for the ISC cohorts. We did not consider epitope 86 as this epitope was
detected in naturally infected koalas in our previous study.
doi:10.1371/journal.pone.0156094.g004
Adjuvant Effect Immune Response in Koalas (Phascolarctos cinereus)
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5B). The effect of these antibodies was confirmed with animal “Cherry” (did not produce any
anti-58 antibodies) and animal “Squeek” (did not produce any anti-77 antibodies) as the in
vitro neutralisation level for these animals was not reduced following absorption against 58 or
77 peptides. We also observed significant in vitro neutralisation by antibodies against peptides
4, 41/42 and 28, with anti-peptide 4 antibodies (especially in the ISC cohort), having a major
effect (Fig 5E).
Discussion
Our previous work suggested that the koala’s immune system is able to mount both effective
cellular and humoral immune responses against a rMOMP vaccine, when administered in
combination with two different adjuvant systems [14–18]. While both adjuvant vaccines look
promising, one requires two or three doses (ISC) while the other is a single administration vac-
cine (Tri-Adj). We therefore decided to directly compare the immune responses of the two vac-
cine formulations using the same rMOMP antigens to vaccinate koalas from the same wild
population.
Studies with the mouse model of C.muridarum show that an IFN-γ response is required for
adequate protection against chlamydial infections. While there is no direct evidence yet for
protection against C. pecorum infections in koalas, vaccine development should aim for a
strong IFN-γ response. We found that both vaccine formulations induced good IFN-γ
responses in 60% of animals that lasted for up to 6 months. No significant difference could be
seen in the specific IFN-γ response induced by the single dose Tri-Adj formulation or the ISC
formulation. IFN-γ activity is the hallmark of the Th1 immune response against chlamydial
infection and IFN-γ gene knockout mice are indeed unable to resolve the infection [29].
Despite the promising IFN-γ response in some animals (60%), not all koalas produced a detect-
able IFN-γ response. The animals in this trial are outbred animals and this highlights key
Major Histocompatibility Complex (MHC) considerations for future vaccine development.
Genetic differentiation and structure analysis has revealed that the koala’s MHC-II gene is
Table 1. Epitopemapping of antibodies in plasma samples at 6 months post vaccination as determined by Pepscan assay. CD: MOMPConserved
domain; VD F1: Variable domain 1 for MOMP F; VD F2: Variable domain 2 for MOMP F; VD F3: Variable domain 3 for MOMP F; VD F4: Variable domain 4 for
MOMP F; VD A: Variable domain 1, 2, 3, 4 for MOMP A; VD G: Variable domain 1, 2, 3, 4 for MOMPG; VD H: Variable domain 1, 2, 3, 4 for MOMP H.
Tri-Adjuvant cohort CD VD F1 CD VD F2 CD VD F3 CD VD F4 CD VD A VD G VD H CD
Cindy 58, 59 77
Greg 28 77
Cherry 4 28
Maxwell 28 41 77
Kylie 41 59 77
Paige 41 58, 59 77
Janke 58, 59 77
Squeek 41, 42
Linky 41 77
Kelly 58 77
ISC cohort CD VD F1 CD VD F2 CD VD F3 CD VD F4 CD VD A VD G VD H CD
Robyn 4 41, 42
Hunky Harry 4 28 86
Pepper 4 28
Winnic 28
Maya 4 28 41
doi:10.1371/journal.pone.0156094.t001
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more diverse in koalas in the northern states of Queensland and New South Wales, compared
to the southern states of Victoria [30, 31]. The higher MHC-II diversity could be the potential
cause of the variable immune response within this group of koalas.
In addition to IFN-γ, IL-17A has been suggested as an important cytokine for chlamydial
infection, both for protection, but potentially also in disease pathology [13, 32]. We observed
Chlamydia-specific IL-17A responses for 40% of koalas with both vaccine formulations.
Whilst, recent studies in koalas [27] and women [33] reported that strong expression of IL-
17A has been associated with clinical chlamydiosis and chlamydial cervicitis, IL-17-/- mice
showed less pathological lesions compared to BALB/c [13]. Moreover, an elevated IL-17A
response has been observed in clinical chlamydial infection in mouse model [34]. Though the
mechanism of IL-17A in pathogenesis is unclear, this study confirms both vaccines can induce
expression of this cytokine.
Fig 5. In vitro neutralisation levels of plasma from vaccinated koalas (A) whole plasma at 1/10 dilution for Tri-Adj cohort, (B) whole plasma after
absorption against peptides 58 and 77, or (C) whole plasma after adsorption against peptides, 4, 28, 41, 42, 58, 59, and 77. Separately, the in vitro
neutralisation of plasma from ISC cohort (D) whole plasma at 1/10 dilution, (E) whole plasma after adsorption against peptide, 4, (F) whole plasma after
adsorption against peptides, 4, 28, 41 and 42. The neutralising antibodies were presented against individual animals and all samples were diluted at
1:10 dilution andC. pecorum EBs (50,000 IFU) were added to samples. The results are expressed as the percentage in neutralisation of immune
samples compared to that of the pre-immune and non-infected samples. The reductions of neutralising antibodies are presented as empty spaces in
the bar. (Panel B: Empty space represents the neutralising anti-epitopes 58 and 77; Panel C: Empty space represents the neutralising anti-epitopes 4,
28, 41, 42, 58, 59 and 77; Panel E: Empty space represents the neutralising anti-epitopes 4; Panel F: Empty space represents the neutralising anti-
epitopes 4, 28, 41 and 42).
doi:10.1371/journal.pone.0156094.g005
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While we did not observe any measurable anti-inflammatory cytokines response in either
group, still their role in chlamydial immunity and pathogenesis is controversial. In general, IL-
10 suppresses the secretion of various pro-inflammatory cytokines involved in chlamydial
pathogenesis [35]. Furthermore, in the mouse model, the IL-10 dominated response has been
attributed with susceptibility to chronic infection [36]. A similar observation has been seen in
trachoma infected populations [37]. The higher expression of the IL-10 gene promoter has
been associated with increased chlamydial infection and disease severity [38]. Similarly, a
higher level of IL-10 has been linked to C. trachomatis infertility [39, 40] and tubal damage in
women [41]. However, koalas with clinical chlamydiosis, expressed IL-10 in variable levels,
with some animals showing higher levels of expression similar to IFN-γ [25, 27]. In a similar
fashion, the role played by TNF-α in chlamydial infection has provided disparate results. How-
ever, TNF-α has been linked to an initial clearance of primary infection but challenge infection
elicited immune-pathology in the mouse [42] and guinea pig model [43]. In the mouse model
studies showed TNF-α produced by CD8+ T cells, promote inflammation in the oviduct fol-
lowing C.muridarum infection [44] but CD4+ T cells producing IFN-γ and TNFα are gener-
ally immune-protective. In contrast, reduced chlamydial shedding following challenge
infection in vaccinated mice, has been attributed to the co-expression of TNF-α and IFN-γ
[45].
While cytokines are considered to be the major immune mechanism for protection against
chlamydial infections, antibodies continue to be considered just as important. In fact, recent
data confirmed the protective roles of antibodies in chlamydial infection in koalas and other
animal studies [46, 47]. If antibodies do play a role in protection, then it will be via their neutra-
lisation role. We therefore measured the in vitro neutralisation ability of plasma antibodies
from animals immunised with the two adjuvants. We evaluated both their total neutralisation
ability but we also determined which peptides within the MOMP protein the antibodies were
directed against and which of these were the most important for the neutralisation effect. This
produced very interesting and promising results for the neutralisation ability of plasma from
vaccinated koalas.
Firstly, both adjuvants produced antibodies that were equally neutralising. This confirms
that MOMP has B cell epitopes that can be neutralising, validating it as a good vaccine target.
Interestingly, the adjuvants resulted in a different, but overlapping, set of vaccine-induced epi-
topes. Three peptides were recognised by both adjuvants (4, 28, and 41/42), but two additional
epitopes (58/59 and 77) were solely recognised by Tri-Adj-immunised animals. The adsorption
experiments nicely confirmed that several anti-epitope antibodies contributed to the in vitro
neutralisation effect. Studies in the non-human primate model utilising native MOMP formu-
lations had previously shown serovar- specific immune response either to homologous serovars
[48] or cross-reacting to the closely related heterologous serovars [49]. Interestingly, in this
study, the vaccine-induced epitopes recognised are all located in the conserved domains sug-
gesting their role in cross-reactive recognition against diversified MOMP genotypes. Several
vaccine studies have used the native form of MOMP, arguing that MOMP in its native should
elicit a more robust immune response [48]. However, this study suggests that rMOMP is capa-
ble of generating neutralising epitopes in koalas. Nonetheless, 80% of the animals responded to
epitope 77 in the variable region, but did not result in extra neutralising capacity.
In summary, both the adjuvants induce Th1-biased immune responses with neutralising
antibodies. It is promising that the single dose Tri-Adj is able to produce a comparable immune
response to the two or three-shot ISC up to 6 months time point. Tri-Adj has proven to be an
effective adjuvant system for koala-Chlamydia vaccine design, and a practicable solution to
eliminate multiple vaccination events. However, the longevity of the response elicited by each
adjuvant in koalas remains to be determined. All of the surviving animals in our original study
Adjuvant Effect Immune Response in Koalas (Phascolarctos cinereus)
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[16] that were immunised with the ISC adjuvant have high plasma antibody levels and memory
CD4 cells 8 years after vaccination, while we don’t yet have similar data for the Tri-Adj. The
identification of key epitopes (for the development of neutralising antibodies) enables future
studies to focus on including these, or to develop specific assays to evaluate vaccine
effectiveness.
Supporting Information
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